ClinicalTrials.Veeva

Menu
The trial is taking place at:
F

Fundacion Scherbovsky | Respiratory Department

Veeva-enabled site

A Study of JNJ-95597528 in Participants With Inadequately Controlled Moderate to Severe Asthma (READY-BREATHE)

Janssen (J&J Innovative Medicine) logo

Janssen (J&J Innovative Medicine)

Status and phase

Enrolling
Phase 2

Conditions

Asthma

Treatments

Drug: JNJ-95597528
Drug: Placebo

Study type

Interventional

Funder types

Industry

Identifiers

NCT07746687
2026-526262-24-00 (Registry Identifier)
95597528ASH2001

Details and patient eligibility

About

The purpose of this study is to assess how well JNJ-95597528 works when compared to placebo in adult participants with moderate to severe asthma (long-term condition that affects the airways in your lungs).

Enrollment

440 estimated patients

Sex

All

Ages

18 to 85 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Medically stable on the basis of physical examination, medical history, and vital signs performed at screening or at baseline
  • Confirmed variable expiratory flow (1 or more of the following) per global initiative for asthma (GINA) 2025 at the baseline visit: a. Evidence of bronchodilator responsiveness at screening and baseline: Post-bronchodilator forced expiratory volume in 1 second (FEV1) increases by greater than or equal to (>=) 200 milliliter (mL) and >=12 percent (%) of pre- bronchodilator value, or increase in peak expiratory flow (PEF) >=20%, if spirometry is not available; b. Demonstrated increase in lung function within the past 3 years after >=4 weeks of daily inhaled corticosteroids (ICS)-containing treatment, shown by: increase from baseline FEV1 by >=12% and >=200 mL, or increase in PEF by >=20%; c. Positive bronchial provocation test within the past 3 years, as defined by: >=20% decrease from baseline in FEV1 with standard doses of methacholine, or >=15% decrease from baseline in FEV1 with standardized hyperventilation, hypertonic saline or mannitol challenge, or decrease from baseline in FEV1 of >10% and >200 mL with standardized exercise challenge
  • Inhaled corticosteroid: Prescribed medium- or high-dose ICS for at least 1 year and a stable dose of medium- or high-dose ICS for at least 3 months prior to the screening visit per GINA 2025: • High-dose ICS is defined as a total daily dose >=500 microgram (mcg) fluticasone propionate or equivalent, • Medium-dose ICS is defined as a total daily dose >=250 to 500 mcg fluticasone propionate or equivalent
  • Additional controller medication: Must be on a stable dose of at least 1 additional maintenance asthma controller, in addition to ICS, per GINA 2025, for at least 3 months prior to screening (for example, long-acting beta-agonist [LABA], long-acting muscarinic antagonist [LAMA] [can be combined with ICS in 1 inhaler or can be separate inhalers], leukotriene receptor antagonist [LTRA])
  • Asthma control questionnaire, 5-item (ACQ-5) score >=1.5 at the screening visit and the baseline visit

Exclusion criteria

  • History of uncontrolled, significant renal, cardiac, vascular, pulmonary (other than asthma), gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances that makes the participant unsuitable for the trial per investigator judgment
  • Any clinically important pulmonary disease other than asthma or pulmonary or systemic diseases, other than asthma, that are associated with elevated peripheral eosinophil counts
  • Experienced primary efficacy failure (no response within 16 weeks) or an adverse event (AE) requiring discontinuation related to agents inhibiting interleukin (IL)-13, IL-4Rα, and IL-4 signaling
  • Participants with either of the following events within the 2 weeks prior to the screening visit: a. Treatment with systemic steroids (oral or parenteral) for worsening asthma, b. Hospitalization or an emergency medical care visit for worsening asthma
  • Current smokers or former smokers with a smoking history >=20 pack-years. Former smokers must have stopped smoking within 6 months of the screening visit. This includes participants using vaping products and e-cigarettes

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

440 participants in 4 patient groups, including a placebo group

Group 1: JNJ-95597528: Dose 1
Experimental group
Description:
Participants will receive JNJ-95597528 Dose 1 at Weeks 0, 2, 12, 24 and 36.
Treatment:
Drug: JNJ-95597528
Group 2: JNJ-95597528: Dose 2 and Dose 3
Experimental group
Description:
Participants will receive JNJ-95597528 Dose 2 at Week 0, placebo at Week 2 then JNJ-95597528 Dose 3 at Weeks 12, 24 and 36.
Treatment:
Drug: Placebo
Drug: JNJ-95597528
Group 3: JNJ-95597528: Dose 4 and 5
Experimental group
Description:
Participants will receive JNJ-95597528 Dose 4 at Week 0, placebo at Week 2 then JNJ-95597528 Dose 5 at Weeks 12, 24 and 36.
Treatment:
Drug: Placebo
Drug: JNJ-95597528
Group 4: Placebo
Placebo Comparator group
Description:
Participants will receive matching placebo doses at Weeks 0, 2, 12, 24, and 36.
Treatment:
Drug: Placebo

Trial contacts and locations

19

Loading...

Central trial contact

Study Contact

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems